BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on immunological recovery remains uncertain. METHODS: During January 1996 through December 2004 [corrected] all patients in the Swiss HIV Cohort were included if they received the first combination antiretroviral therapy (cART) and had known baseline CD4(+) T cell counts and HIV-1 RNA values (n = 3293). For follow-up, we used the Swiss HIV Cohort Study database update of May 2007 [corrected] The mean (+/-SD) duration of follow-up was 26.8 +/- 20.5 months. The follow-up time was limited to the duration of the first cART. CD4(+) T cell recovery was analyzed in 3 different treatment groups: nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4(+) T cell count in the 3 treatment groups after the initiation of cART. RESULTS: Two thousand five hundred ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%) initiated an NNRTI regimen, and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4(+) T cell count increases at 48 months were as follows: in the nonboosted-PI group, from 210 to 520 cells/muL; in the NNRTI group, from 220 to 475 cells/muL; and in the boosted-PI group, from 168 to 511 cells/muL. In a multivariate analysis, the treatment group did not affect the response of CD4(+) T cells; however, increased age, pretreatment with nucleoside reverse-transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers for Disease Control and Prevention stage C infection, lower baseline CD4(+) T cell count, and lower baseline HIV-1 RNA level were risk factors for smaller increases in CD4(+) T cell count. CONCLUSION: CD4(+) T cell recovery was similar in patients receiving nonboosted PI-, NNRTI-, and boosted PI-based cART.
BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on immunological recovery remains uncertain. METHODS: During January 1996 through December 2004 [corrected] all patients in the Swiss HIV Cohort were included if they received the first combination antiretroviral therapy (cART) and had known baseline CD4(+) T cell counts and HIV-1 RNA values (n = 3293). For follow-up, we used the Swiss HIV Cohort Study database update of May 2007 [corrected] The mean (+/-SD) duration of follow-up was 26.8 +/- 20.5 months. The follow-up time was limited to the duration of the first cART. CD4(+) T cell recovery was analyzed in 3 different treatment groups: nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4(+) T cell count in the 3 treatment groups after the initiation of cART. RESULTS: Two thousand five hundred ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%) initiated an NNRTI regimen, and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4(+) T cell count increases at 48 months were as follows: in the nonboosted-PI group, from 210 to 520 cells/muL; in the NNRTI group, from 220 to 475 cells/muL; and in the boosted-PI group, from 168 to 511 cells/muL. In a multivariate analysis, the treatment group did not affect the response of CD4(+) T cells; however, increased age, pretreatment with nucleoside reverse-transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers for Disease Control and Prevention stage C infection, lower baseline CD4(+) T cell count, and lower baseline HIV-1 RNA level were risk factors for smaller increases in CD4(+) T cell count. CONCLUSION:CD4(+) T cell recovery was similar in patients receiving nonboosted PI-, NNRTI-, and boosted PI-based cART.
Authors: Richard C Waters; Jan Ostermann; Travis D Reeves; Max F Masnick; Nathan M Thielman; John A Bartlett; John A Crump Journal: J Acquir Immune Defic Syndr Date: 2011-04-15 Impact factor: 3.731
Authors: Emilie Lanoy; Margaret May; Amanda Mocroft; Andrew Phillip; Amy Justice; Geneviève Chêne; Hansjakob Furrer; Timothy Sterling; Antonella D'Arminio Monforte; Lluís Force; John Gill; Ross Harris; Robert S Hogg; Jürgen Rockstroh; Mike Saag; Pavel Khaykin; Frank de Wolf; Jonathan A C Sterne; Dominique Costagliola Journal: AIDS Date: 2009-10-23 Impact factor: 4.177
Authors: Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan Journal: AIDS Res Ther Date: 2010-05-27 Impact factor: 2.250
Authors: Alan R Lifson; Elizabeth M Krantz; Lynn E Eberly; Matthew J Dolan; Vincent C Marconi; Amy C Weintrob; Nancy F Crum-Cianflone; Anuradha Ganesan; Patricia L Grambsch; Brian K Agan Journal: AIDS Res Ther Date: 2011-01-18 Impact factor: 2.250
Authors: Jeffrey A Boatman; Jason V Baker; Sean Emery; Hansjakob Furrer; David M Mushatt; Dalibor Sedláček; Jens D Lundgren; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Frederik N Engsig; Robert Zangerle; Olga Katsarou; Francois Dabis; Peter Reiss; John Gill; Kholoud Porter; Caroline Sabin; Andrew Riordan; Gerd Fätkenheuer; Félix Gutiérrez; Francois Raffi; Ole Kirk; Murielle Mary-Krause; Christoph Stephan; Patricia Garcia de Olalla; Jodie Guest; Hasina Samji; Antonella Castagna; Antonella d'Arminio Monforte; Adriane Skaletz-Rorowski; Jose Ramos; Giuseppe Lapadula; Cristina Mussini; Lluís Force; Laurence Meyer; Fiona Lampe; Faroudy Boufassa; Heiner C Bucher; Stéphane De Wit; Greer A Burkholder; Ramon Teira; Amy C Justice; Tim R Sterling; Heidi M Crane; Jan Gerstoft; Jesper Grarup; Margaret May; Geneviève Chêne; Suzanne M Ingle; Jonathan Sterne; Niels Obel Journal: Clin Infect Dis Date: 2014-01-22 Impact factor: 9.079
Authors: Carlo Torti; Antonella d'Arminio-Monforte; Anton L Pozniak; Giuseppe Lapadula; Giuliana Cologni; Andrea Antinori; Andrea De Luca; Cristina Mussini; Antonella Castagna; Paola Cicconi; Lorenzo Minoli; Andrea Costantini; Giampiero Carosi; Hua Liang; Bruno M Cesana Journal: BMC Infect Dis Date: 2011-01-25 Impact factor: 3.090
Authors: Reena Rajasuriar; Maelenn Gouillou; Tim Spelman; Tim Read; Jennifer Hoy; Matthew Law; Paul U Cameron; Kathy Petoumenos; Sharon R Lewin Journal: PLoS One Date: 2011-06-02 Impact factor: 3.240
Authors: Boris Julg; Danielle Poole; Musie Ghebremichael; Carmen Castilla; Marcus Altfeld; Henry Sunpath; Richard A Murphy; Bruce D Walker Journal: PLoS One Date: 2012-02-14 Impact factor: 3.240